Resumo

MOLINERO MUNOZ, M; ZAMORA BARRIOS, MD  e  MARTINEZ SESMERO, JM. Effectiveness and safety of immune ckeckpoint inhibitors on patients excluded from clinical trials. Rev. OFIL·ILAPHAR [online]. 2020, vol.30, n.4, pp.325-328.  Epub 25-Maio-2021. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x2020000400012.

In recent years, immunotherapy has revolutionized the treatment of cancer and remains the main objective of many lines of research. Immune checkpoint inhibitors (ICIs) are a very attractive alternative treatment because they have been achieved better response rates and long-term survival rates in several types of cancer. Furthermore, ICIs have favorable tolerance profiles and immune related adverse events (irAEs) do not usually result in significant morbidity and most patients enjoy an excellent quality of life with minimal symptoms during treatment.

However, there is a gap in knowledge on the safety and effectiveness of ICIs in patients who are often excluded from clinical trials due to their characteristics, making it difficult to infer the results of clinical trials to these patients. They are patients with autoimmune diseases or with a compromised immune system (solid organ/hematological transplant patients or with chronic viral infections). The aim of this review is to extend current knowledge of the use of ICIs in these patients, in clinical practice and to propose new research topics.

Palavras-chave : Checkpoint inhibitors; immunotherapy; transplant; autoimmune; CTLA-4; PD-1; human immunodeficiency virus; viral infection.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )